Lanifibranor, a pan-PPAR agonist, targets all PPAR isoforms and has been reported to drive hepatic macrophages to acquire an anti-inflammatory phenotype in experimental models of NASH induced by diet and chronic toxic injury via chronic CCl4 administration (189). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.